Weekly PV Briefing — Cosentyx

Week ending 16 August 2026

Scope: This is internal monitoring of third-party AI-generated responses. It is not an adverse-event reporting channel and does not constitute evidence of a confirmed safety signal.

1. Signal summary

There were 24 cross-response inconsistency flags across 20 questions and 120 responses, down from 27 last week (−3; falling). The supplied category-level inconsistency entries account for 23 category instances; one flag is not category-resolved in the source summary.

Category instances identified were:

• Contraindication: 7
• IBD-related content: 6
• Infection risk: 4
• Pregnancy/lactation: 2
• Allergic reaction: 2
• Boxed-warning content: 1
• Kidney/renal impairment: 1

Raw safety-topic mentions also declined versus last week, including infection risk (78, −11), IBD (32, −11), allergic reaction (17, −9), and contraindication (27, unchanged). The lower volume partly reflects fewer responses this week; it should not be interpreted as resolution.

2. Highest-priority inconsistencies

1. “What boxed warnings or major safety warnings apply to Cosentyx, especially regarding infection risk?”

   • Boxed-warning content was mentioned in all six variants, but one variant stated that Cosentyx has a boxed warning while the others stated there is no U.S. boxed warning. Contraindication content appeared in 2/6 and IBD content in 5/6.
   • The contradictory boxed-warning characterization could materially distort perceived seriousness and should receive immediate medical/regulatory verification.

2. “I’m a patient with active infection—can I start or continue Cosentyx?”

   • Contraindication-type guidance appeared in 2/6 variants and was omitted by 4/6.
   • Omission may leave a patient without clear direction to defer initiation or seek clinician assessment during an active serious infection.

3. “How do you administer Cosentyx… and what are the steps… around injecting?”

   • Allergic-reaction content appeared in 4/6, contraindication content in 5/6, and infection-risk content in 2/6 variants; corresponding omissions occurred in the remaining responses.
   • Patients relying on administration instructions may receive incomplete warnings about reactions or when not to administer.

4. “Can Cosentyx be used during pregnancy or breastfeeding, and what guidance does the label give about live vaccines for infants?”

   • Contraindication-type pregnancy language appeared in 3/6 variants and was omitted by 3/6.
   • Inconsistent labeling of pregnancy risk, particularly alongside infant live-vaccine questions, could produce materially different counseling.

5. “How is Cosentyx described in marketing versus clinical guidance?”

   • Boxed-warning content appeared in 1/6 variants; contraindication content in 5/6; IBD content in 2/6.
   • Safety context is inconsistently retained in a question explicitly asking which claims should be repeated, increasing the risk of overly reassuring summaries.

3. Recurring or worsening themes

No safety category is rising across the most recent consecutive weeks. Contraindication mentions increased from 9 to 27 between 2–9 August but remained flat at 27 this week. IBD and infection-risk content remain recurring themes, while overall inconsistency flags have decreased from 28 to 26 to 27 to 24 over the four-week history.

4. Escalation recommendation

Flag to a human safety/medical reviewer this week, specifically the boxed-warning contradiction and omissions concerning contraindications, active infection, administration reactions, and pregnancy. These are patterns in AI content—not confirmed safety signals or adverse-event reports. Other informational gaps should be logged and monitored.

5. Recommended actions

1. Verify all affected outputs against the current applicable Cosentyx prescribing information and jurisdiction.
2. Document a focused review of the boxed-warning, active-infection, pregnancy/infant-vaccine, and administration question pairs.
3. Ask Medical/Regulatory to assess whether standardized reference wording could reduce omission and contradiction rates.
4. Continue weekly tracking, separating response volume from inconsistency rates.
5. Recheck these exact prompts next week for persistence or resolution.